Gilead Sciences

Gilead Sciences Inc (ticker GILD, listed on NASDAQ) is a biotech company headquartered in Foster City, CA (USA).
The company's activities include clinical drug research, development and commercialisation. Its primary focus is antiviral medication for the treatment of HIV, Hepatitis B, Hepatitis C and influenza.
Gilead Sciences Inc was founded in June 1987 by Michael L. Riordan,  a medical doctor who was 29 years old at the time.
The company employs 11800 people.

Turnover
The company posted 2019 earnings of $22,449M.

Image
Gilead has been on the receiving end of some scathing criticism over the high price of its patented drug, Sofosbuvir. In the US, for example, it was marketed with a price of $1000 per tablet, or $84,000 for a standard 84-day course.
Currently, the lion's share of the company's earnings is generated by its range of HIV medication. Sales of these drugs are growing steadily as Gilead Sciences Inc enjoys a near monopoly in the US, with 86% of patients using the company's medication.

Share price and listings
The company's shares are weighted in the NASDAQ 100 and S&P 500 indices and
 there are a total of 1.264 billion in circulation. Gilead has market capitalisation in excess of $91 billion.

Potential return
Gilead Sciences Inc has enjoyed virtually uninterrupted share price growth since it was listed, except for one correction from 2008-2010 as a result of the financial crisis. Over a period of 20 years from 1995 to 2015, the company's share price has risen by 20,000%!  There aren't many companies in the world that can boast that sort of performance. During the first two months of 2020, GILD rose by 8%! One way to significantly increase the amount of profit you could make from buying CFDs in Gilead is the use of leverage (multiplier).